The thiophene moiety is considered a structural alert in molecular design in drug discovery, largely because several thiophene-containing drugs, including tienilic acid and suprofen, have been withdrawn from the market because of toxicities. Reactive thiophene intermediates, activated via sulfur oxidation or ring epoxidation, are possible culprits for these adverse side effects. In this work, the metabolic activation of an anti-inflammatory agent, 1-(3-carbamoyl-5-(2,3,5-trichlorobenzamido)thiophen-2-yl)urea), containing a 2,5-diaminothiophene structure, was studied in liver microsomes in the presence of glutathione or N-acetylcysteine as trapping agents. In addition, the glutathione conjugate was detected in bile from a bile duct-cannulated rat study. The structure of the glutathione conjugate was identified by mass spectrometry and 1 H NMR. The glutathione molecule was attached to the thiophene ring, replacing the existing proton. Metabolic phenotyping experiments, using chemical inhibitors or recombinant cytochromes P450 (P450), demonstrated that CYP3A4 was the major P450 enzyme responsible for the metabolic activation, followed by CYP1A2, 2Cs, and 2D6. A novel metabolic activation mechanism is proposed whereby the 2,5-diaminothiophene moiety undergoes oxidation to a 2,5-diimine thiophene reactive intermediate. This mechanism was used to support efforts to eliminate reactive metabolite generation via structural modification of ring substituents using structure-activity relationships. The disruption of formation of the 2,5-diimine reactive intermediate resulted in the elimination of glutathione conjugate formation both in vitro and in vivo and provided a rational approach to mitigating potential safety risks associated with this class of thiophenes in drug research and development.
Introduction
Adverse drug effects, including idiosyncratic drug reactions, have resulted in the withdrawal of a number of drugs from the market over the past several years (Smith and Schmid, 2006) . Idiosyncratic drug reactions are unpredictable and are believed to be related to metabolic activation, i.e., the formation of chemically reactive intermediates/ metabolites that covalently bind to proteins and result in the failure of their primary biological functions or stimulation of abnormal immune responses (Ju and Uetrecht, 2002; Uetrecht, 2006 Uetrecht, , 2008 . As a result, reactive metabolites have become an important issue in modern drug discovery and development. Whether or not protein modification by reactive metabolites results in toxicity depends on many factors, including the function and consequence of the modified targets (covalently bound enzymes/receptors), dose and absorption of drugs, pharmacokinetic profile of the parent drug, fraction of reactive metabolites formed, and detoxification capacity for the reactive species, individual variability, and susceptibility (Obach et al., 2008; Bauman et al., 2009; Gan et al., 2009; Nakayama et al., 2009 ). P450s are the major metabolizing enzymes that transform lipophilic xenobiotics to hydrophilic metabolites for direct elimination or further conjugation and therefore play an important role in the detoxification of drugs. However, some metabolites or metabolic intermediates contain highly reactive electrophilic groups such as quinones, quinone imines, quinone methides, epoxides, or nitrenium/nitroso groups. These reactive metabolites are known to covalently bind to proteins and DNA and have been linked to numerous toxicities. Chemical structures that can be metabolically transformed to reactive groups and produce potential adverse safety outcomes are considered "structural alerts."
The five-membered heteroaromatic thiophene is a useful isosteric building block that is widely used in drug design. The metabolism of thiophene is mainly mediated by P450 enzymes via hydroxylation at carbon atoms adjacent to the sulfur atom (Dansette et al., 1990; Dalvie et al., 2002) . However, thiophene-containing drugs and chemicals, such as tienilic acid (TA), suprofen, tenidap, ticlopidine, and methapyrilene exhibit various toxicities in humans and animals (Liu and Uetrecht, 2000; Nelson, 2001; Graham et al., 2008; Johnson, 2008) . This is generally attributed to the reactive intermediates derived from P450-mediated oxidative metabolic activation (Dansette et al., 1991; Lopez Garcia et al., 1993) . Therefore, thiophene is regarded as a structural alert. In some cases, the reactive metabolites inactivate the enzyme catalyzing their own formation (mechanism-based inhibition). For instance, TA, a diuretic drug, and suprofen, an anti-inflammatory agent, are metabolically activated by CYP2C9. At the same time, both drugs inactivate CYP2C enzymes (López-Garcia et al., 1994; Jean et al., 1996; O'Donnell et al., 2003; Masubuchi and Horie, 2007; Hutzler et al., 2009) . The metabolic activation of thiophene derivatives has been suggested to occur via sulfur oxidation or an epoxidation mechanism (Dansette et al., 1992 (Dansette et al., , 2005 Valadon et al., 1996; O'Donnell et al., 2003; Medower et al., 2008) . The resulting toxicities of thiophenes are thought to be related to the formation of these reactive metabolites. For example, TA, with an arylcarbonyl substitution at position 2, induced hepatitis in humans (Zimmerman et al., 1984) . It binds to microsomal protein nonspecifically, but also binds to CYP2C9 specifically and inactivates this enzyme. The drug-bound CYP2C9 induced formation of the autoimmune antibody anti-LKM 2 , which was detected in patients with TA-induced immunoallergic hepatitis (Homberg et al., 1984; Beaune et al., 1987; Lecoeur et al., 1996) . These antibodies (anti-KLM 2 ) recognize a three-site conformational epitope on CYP2C9.
In vitro, the addition of GSH prevented the external nonspecific covalent binding, but not the inactivation of CYP2C9. An isomer of tienilic acid, with arylcarbonyl substitution at position 3, is metabolically activated by CYP2C9 and binds to microsomal protein nonspecifically but is not a mechanism-based inhibitor (Mansuy, 1997; Bonierbale et al., 1999; Dalvie et al., 2002) . In vitro, the addition of GSH prevented covalent microsomal binding. It is interesting to note that the TA isomer exhibited direct liver toxicity in rats (Bonierbale et al., 1999) . This revealed that the chemical structure of thiophene derivatives, i.e., substitution patterns on the thiophene ring, is a major determinant of differentiation in the metabolic activation mechanism, the reactive species formed, and distinct toxicities.
The understanding of structural alerts and their metabolic activation mechanism(s) is a critical step in an approach to finding a solution to drug-induced toxicities in the drug discovery setting. Structural modifications that eliminate the formation of reactive intermediates can be identified by a knowledge of structure-activity relationships (SARs), thus minimizing potential risk in further drug development and reducing attrition and cost (Evans et al., 2004) . In addition, an understanding of the in vivo elimination of a drug and its reactive metabolite in preclinical animals, its pharmacokinetics, and its toxicological translation from animals to human is important to bringing a safe drug to market. In vitro screening in hepatic systems (liver microsomes, S9, or hepatocytes) with supplemented thiol-trapping agents [GSH or N-acetylcysteine (NAC) ], in conjunction with in vivo bile duct-cannulated animal experiments are useful tools in metabolism and reactive metabolite investigation and safety assessment.
The metabolic activation mechanisms of a variety of thiophenecontaining compounds, including suprofen, TA, and ticlopidine, have been investigated. Among them, the most common structure variations on the thiophene ring are carboxamide or aromatic/heteroaromatic substitutions. No diamino-substituted thiophenes have been studied for reactive metabolite formation. This work focuses on the metabolic activation of a series of anti-inflammatory agents containing mono-or diaminothiophene groups (Fig. 1) . Reactive metabolites trapped by thiol-containing agents were isolated, and their structures were identified. These patterns of substitution on thiophene and their metabolic activation have not been reported in the literature. Based on the SARs observed with this series of compounds, a novel metabolic activation mechanism for thiophene derivatives is proposed.
Materials and Methods
Chemicals and Reagents. The thiophene-containing compounds 1 to 14 were synthesized internally and obtained from archive storage at Pfizer Global Research and Development (St. Louis Laboratories, St. Louis, MO). GSH, NAC, furafylline, sulfaphenazole, quinidine, ketoconazole, and NADPH (tetrasodium salt) were purchased from Sigma-Aldrich (St. Louis, MO), and HPLC-grade acetonitrile was purchased from VWR (West Chester, PA). Pooled human liver microsomes, rat liver microsomes, recombinant human cytochrome P450 enzymes, and recombinant human flavin-containing monooxygenase were purchased from BD Biosciences (San Jose, CA). Male Sprague-Dawley rats were purchased from Harlan (Indianapolis, IN).
Metabolic Activation and Trapping Assay. The metabolic activation of thiophene-containing compounds was conducted with liver microsomes (pooled male Sprague-Dawley rat or pooled human) in the presence of GSH. Compounds 1 to 14 (10 M) were incubated in potassium phosphate buffer (100 mM, pH 7.4) containing microsomal protein (0.5 mg/ml), GSH or NAC (5 mM), and an NADPH-regenerating system (1 mM NADPH, 5 mM glucose 6-phosphate, and 1 unit/ml glucose-6-phosphate dehydrogenase). After a 5-min preincubation at 37°C, NADPH was added to the mixture to initiate metabolic activation, and the reaction proceeded for 30 to 60 min on a Thermomixer (Eppendorf North America, Hauppauge, NY) at 350 rpm. Reactions were stopped by the addition of an equal volume of acetonitrile. The mixtures were centrifuged at 14,000 rpm for 10 min, and the resulting supernatants were injected onto an HPLC/UV/MS system for analysis. In the case of samples used for detailed structure identification via NMR, the supernatants were pooled and dried down by a CentriVap Vacuum Concentrator System (Labconco, Kansas City, MO) to yield a crude solid mixture for further purification.
Metabolic Activation Enzyme Phenotyping. Enzymes responsible for the metabolic activation of the thiophene derivatives were determined by 1) incubation with human liver microsomes in the presence of specific P450 inhibitors and 2) incubation with individual cDNA-expressed recombinant human metabolizing enzymes. The phenotyping assays were performed with a 2,5-diaminothiophene (compound 1, 10 M) in 1) human liver microsomes (0.5 mg/ml), with or without specific P450 inhibitors (furafylline for CYP1A2 at 10 M, sulfaphenazole for CYP2C9 at 10 M, quinidine for CYP2D6 at 2 M, or ketoconazole for CYP3A4 at 0.5 M) or 2) with cDNA-expressed human P450 enzymes (50 nM), including CYP1A2 (Ϫb 5 
, and 3A5 (ϩ b 5 ), or cDNA-expressed human FMO enzymes (0.5 mg/ml), including FMO1 and FMO3, in the presence or absence of GSH (5 mM), an NADPH-regenerating system (1 mM NADPH, 5 mM glucose 6-phosphate, and 1 unit/ml glucose-6-phosphate dehydrogenase) in potassium phosphate buffer (100 mM, pH 7.4). After a 5-min preincubation at 37°C, NADPH was added to the mixture to initiate metabolic activation, and the reaction proceeded for 30 min on a Thermomixer at 350 rpm. Reactions were stopped by the addition of an equal volume of acetonitrile, and the resulting supernatants were injected onto an HPLC/UV/MS system. The relative amounts of GSH conjugates, parent compound, and other metabolites were quantitated by UV at wavelengths ranging from 250 to 350 nm.
Isolation and Purification of GSH Conjugate. GSH conjugates were initially purified by solid-phase extraction using an Oasis HLB cartridge (Waters, Milford, MA). The cartridge was preequilibrated with methanol and water. Crude reaction mixtures from supernatants were loaded onto the FIG. 1. Structure of thiophene derivatives. Compound 1 (2,5-diaminothiophene), 1-(3-carbamoyl-5-(2,3,5-trichlorobenzamido)thiophen-2-yl)urea; compound 7 (2-aminothiophene), 1-(3-carbamoyl-5-((3-chlorophenyl)carbamoyl)-thiophen-2-yl)urea; and compound 11 (2,4-diaminothiophene), 1-(2-carbamoyl-5-(quinoline-4-carboxamido) thiophen-3-yl)urea.
column and sequentially eluted with 5 ml of water, 5 ml of 5% methanol in water, 5 of 50% methanol in water, and 5 ml of 100% methanol. Eluents were collected in glass tubes and fractions containing the desired GSH conjugate were concentrated. Further purification was carried out on a HPLC-MS system containing a ThermoFinnigan LCQ ion trap mass spectrometer equipped with an Agilent 1100 HPLC system, a Phenomenex Gemini C18 column (4.6 ϫ 250 mm, 5 um), and a fraction collector (Gilson 215 Liquid Handler). Sample aliquots (100 l) were injected onto the column using a flow rate of 1.5 ml/min. Initial mobile phase conditions were 5% mobile phase B (mobile phase A: water with 0.1% formic acid; mobile phase B: acetonitrile with 0.1% formic acid) for 1 min, followed with a gradient to 95% mobile phase B in 30 min, which was maintained for 1 min, then immediately returned to the initial conditions in 1 min, and held for 3 min. Fractions were collected into a 96-well microtiter plate and monitored by a UV detector with a photodiode array range of 200 to 400 nm and an ion trap mass spectrometer in electrospray ionization positive mode with a Q1 full-scan range from 150 to 1000 m/z. Fractions containing a single GSH conjugate were pooled and dried. A purified GSH conjugate was sent for NMR characterization.
Instrumentation and Metabolic Identification. All samples from the supernatants were analyzed using a ThermoFinnigan TSQ Quantum triple quadrupole mass spectrometer coupled with an Agilent 1100 HPLC system and an UV detector. GSH conjugates of the thiophene compounds and other metabolites were identified by Q1 full scan and quantified by UV. Datadependent acquisition was conducted to obtain detailed structural information. Samples (10 l) were injected onto an Agilent Zorbax C18 column (2.1 ϫ 150 mm, 3.5 m) at a flow rate of 400 l/min. The elution gradient started with 20% mobile phase B for 2 min, which was then increased to 95% mobile phase B in 10 min and held for 2 min, followed by a return to the initial condition of 20% mobile phase B in 2 min with maintenance for 4 min. UV detection covered the range of 200 to 400 nm. Parent thiophenecontaining compounds and their GSH or NAC conjugates from in vitro assays were quantitated at wavelengths of 250 to 350 nm. A narrower range of wavelengths (320 -325 nm) was used to quantitate in vivo bile samples to avoid interference from endogenous compounds. The positive electrospray ionization mode was used for the MS analysis with a capillary temperature of 270°C, sheath gas nitrogen at 60 psi, auxiliary gas nitrogen at 20 psi, and a detection mass range of 150 to 1000 m/z.
For the definitive structure identification, NMR spectra of the purified GSH conjugate of compound 1 (approximately 3-10 g at 90% purity) was acquired on an Unity Inova 500 MHz narrow-bore high-resolution NMR spectrometer, equipped with a 5 mm 1 H-13 C pulsed field gradient indirect detection cryoprobe. The one-dimensional proton NMR spectra were taken at 30°C, collecting 256 transients. The two-dimensional gradient heteronuclear single quantum correlation spectrum was conducted at 30°C with 512 transients, 1.0-s relaxation delay, 4-kHz 1 H spectral width, and wideband, uniform rate, and smooth truncation 13 C decoupling (bandwidth 40 kHz). The gradient heteronuclear multiple-bond correlation spectrum was obtained at 30°C with 1536 transients, 1.0-s relaxation delay, wideband, uniform rate, and smooth truncation 13 C decoupling (bandwidth 40 kHz), and use of a square sinebell weighting function in both domains.
In Vivo Reactive Metabolite Study and GSH Conjugates Formation. The in vivo formation of reactive metabolites derived from thiophenecontaining compounds was evaluated in rats. Bile duct cannulation was performed in house. Male Sprague-Dawley rats were fasted overnight before surgery. Twenty microliters of warm saline was injected subcutaneously before surgery to improve hydration. Animals were anesthetized with inactin (100 mg/kg) and remained on heating pads during anesthesia and surgery and for the duration of the study. A 3-cm midline incision was made caudally from the xiphoid process. The upper 20 cm of the duodenum was identified and held intact outside the body cavity in warm salinesoaked gauze. The common bile duct was cannulated using PE10 tubing and held in place with 5-0 suture. The thiophene-containing test compounds were formulated in PEG-400-water-Tween 80 (40:45:5) and administered intravenously at a dose of 5 mg/kg. Bile fluids were collected at time intervals of 15, 30, 45, 60, 90, 120, 180 , and 240 min. The crude bile fluids were diluted 1:1 with water, followed with 5 volumes of acetonitrile. Precipitated proteins were removed after centrifugation at 14,000 rpm for 10 min. Supernatants were injected onto the HPLC/UV/MS system. GSH conjugates were identified by MS and quantitated by UV at a wavelength of 320 to 325 nm.
The St. Louis Pfizer Institutional Animal Care and Use Committee reviewed and approved the animal use in these studies. The animal care and use program is fully accredited by the Association for Assessment and Accreditation of Laboratory Animal Care, International. 
Results
Reactive Metabolite Formation and Identification of GSH and NAC Conjugates in Liver Microsomes. Thiophene derivative compound 1 was incubated with rat or human liver microsomes in the presence or absence of cysteine-containing agents (GSH and NAC). Resulting supernatants were injected onto a high-performance liquid chromatograph equipped with both UV and MS detectors. No significant metabolites were detected in the absence of GSH (data not shown). From the samples incubated with GSH, two major peaks were observed at retention times of 7.30 and 6.28 min, respectively (UV chromatogram) ( Fig. 2A) . Compared with an authentic standard, the former peak was confirmed as the parent compound 1 by MS (Fig.  2C ) with molecular weights of 407 (M ϩ H), 409 (M ϩ 2 ϩ H) and 411 (M ϩ 4 ϩ H) and the expected isotope pattern for the three chlorine atoms (M:M ϩ 2:M ϩ 4 at 3:3:1). The latter peak also contained an isotope pattern for the three chlorine atoms and the molecular weights of parent compound plus 305, correspondingly (Fig. 2D) . This suggested the addition of GSH (molecular weight 307) to the parent 2,5-aminothiophene (compound 1), followed by the loss of 2 protons and can be explained as a nucleophilic substitution of the GSH to an unsaturated aromatic/heteroaromatic system, such as thiophene or phenyl. Furthermore, the product ion spectra of the GSH conjugates revealed more detailed structural information (Fig. 3) . A typical daughter ion of GSH fragment is related to the loss of glutamic acid (129 atomic mass units, m/z at 583), and a series of daughter ions are associated with the fragmentation of the GSH tripeptide. A unique fragment at m/z 207 suggested an intact trichlorobenzoic ion moiety. Therefore, the GSH is believed to be added to the thiophene portion not the phenyl ring. Compound 1 also formed a covalent conjugate with NAC. Even though the patterns of MS/MS fragmentation are different from those of the GSH conjugate, it contains the same distinct fragment of intact trichlorobenzoic moiety at m/z 207 (Fig. 4) . 
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Therefore, the NAC moiety is present on the thiophene ring as well.
The definitive structure identification was achieved by 1 H NMR (Fig. 5, A and B ; Table 1 ). First, the parent compound 1 and GSH were fully analyzed by one-dimensional and two-dimensional 1 H NMR, and their chemical shifts were assigned. Then, the proton NMR of the GSH conjugate was acquired and compared with that of the parent compound and GSH. Analysis with special attention to both the chemical shift and peak splitting pattern showed that the two meta-positioned aromatic protons (H23 and H25) on the trichlorophenyl ring remain intact as two doublets at 7.67 and 7.78 ppm, respectively, with a coupling constant of 2.19 Hz. The aromatic proton on the thiophene ring (H3) in the parent compound is at 6.96 ppm (methanol-d4). This proton signal disappeared in the GSH conjugate, clearly demonstrating that the GSH is attached to the C3 position of compound 1. Furthermore, it was confirmed that Metabolic Enzyme Phenotyping for Bioactivation of 2,5-Diaminothiophene. Endoplasmic reticulum membrane-bound cytochrome P450s are major metabolizing enzymes involved in the elimination of endogenous compounds and xenobiotics. In some cases, P450 enzymes generate highly active metabolites that can covalently bind to cellular components, including protein, DNA, or other endogenous biological molecules. In particular, CYP3A4 has been found to metabolize a variety of drugs and itself is inactivated by reactive intermediates (Zhou et al., 2005; Zhou, 2008) . CYP2C9 was found to catalyze the metabolic activation of thiophene-containing drugs, such as suprofen and TA, and is inactivated by these drugs via mechanismbased inhibition (López- Garcia et al., 1994; Jean et al., 1996; O'Donnell et al., 2003; Hutzler et al., 2009 ). The 2,5-diaminothiophene derivative (compound 1) formed GSH conjugates by microsomal enzymes in the presence of NADPH, suggesting that it is an NADPH-dependent oxidative metabolic activation mediated by membrane-bound P450 or FMO enzymes. The individual oxidative enzymes that converted compound 1 to reactive metabolite(s) were examined. First, the assay was conducted in human liver microsomes with specific P450 inhibitors in the presence of GSH (Fig. 6 ). The formation of GSH conjugate was measured and set as 100% when inhibitors were not used. Ketoconazole inhibited 79% of GSH conjugate formation, followed by furafylline (32%), sulfaphenazole (16%), and quinidine (Ͻ5%). These results demonstrated that multiple P450 enzymes were involved in the metabolic activation of compound 1. Among them, CYP3A was the major P450 enzyme contributing to the formation of GSH conjugates, followed by CYP1A2, CYP2C, and CYP2D6 in human liver microsomes. Furthermore, cDNA-expressed recombinant human P450 and FMO enzymes were used to confirm these findings (Fig. 7) . In general, these results followed the same trend as with human liver microsomes in that multiple P450 enzymes converted compound 1 to a reactive intermediate, which was further trapped by GSH. Among them, CYP3A4 was the most active P450 enzyme catalyzing the metabolic activation of compound 1, followed by CYP3A5 and CYP1A2. CYP2D6 was a little more reactive than CYP2C9, but its contribution in human liver microsomes was negligible, probably due to the low expression level of CYP2D6 in human liver compared with that of CYP2Cs. FMO1 and FMO3 did not yield GSH conjugates.
Structure-Metabolic Activation Relationship of Thiophene Derivatives and In Vitro/In Vivo Correlation. To investigate the metabolic activation mechanism of diaminothiophene derivatives, a variety of structurally modified diaminothiophene derivatives were selected for testing. These are categorized as 2,5-diaminothiophene derivatives, 2-aminothiophene derivatives, and 2,4-diaminothiophene derivatives, as shown in Tables 2, 3 , and 4, respectively. In vitro assays were performed with each test compound as described previously with a rat liver microsomal system in the presence of GSH or NAC. Parent compounds, stable metabolites, and reactive metabolites (trapped as GSH or NAC conjugates), were quantified by UV at wavelengths of 250 to 350 nm. Their total amount was set as 100%; therefore, the relative amount of reactive metabolites (GSH or NAC conjugates) was calculated. In most cases, only parent compounds, plus GSH or NAC conjugates were observed on the UV chromatogram, without any significant amount of other oxidative metabolites. Six 2,5-diaminothiophene derivatives (compounds 1-6) formed GSH or NAC conjugates ( Table 2 ). The relative amount of GSH or NAC conjugates accounted for approximately 10 to 70% of the total amount (parent plus conjugates) under these experimental conditions, with no other metabolites observed. Four 2-aminothiophene derivatives (compounds 7-10) were tested under the same conditions. None of them formed either GSH or NAC conjugates (Table 3) . Instead, compound 8 underwent extensive hydrolysis, probably catalyzed by a microsomal FIG. 6 . Metabolic activation enzyme phenotyping of 2,5-diaminothiophene compound 1 in human liver microsomes by a specific P450 inhibitor. Percent formation of GSH conjugate with and without a P450 inhibitor: 100% (no inhibitor), 67% (furafylline), 84% (sulfaphenazole), 96% (quinidine), and 21% (ketoconazole). ‫,ء‬ statistically significant (P Ͻ 0.05). dmd.aspetjournals.org esterase, whereas compound 9 mainly proceeded with N-demethylation by P450s. The key structural feature of the 2-aminothiophene series of derivatives was the reverse orientation of the amide linker, such that the carboxyl group was now adjacent to the thiophene ring rather than the amine.
Finally, four 2,4-diaminothiophene derivatives (compounds 11-14) were tested with GSH only. No GSH conjugates were detected in the incubation preparations. Oxidation of compound 11 was observed as the major metabolite. In other cases of 2-aminothiophene derivatives and 2,4-diaminothiophene derivatives, only the parent compounds were detected by UV and MS. The key structural feature of the 2,4-diaminothiophene series of derivatives was the movement of the second amine moiety from C5 to C4, leaving only one amine group adjacent to the sulfur atom (C2). These findings clearly demonstrated a SAR between the location of amine substituents on the thiophene ring and their ability to form reactive metabolites and GSH conjugates.
The metabolic activation of diaminothiophene derivatives was further examined in vivo to investigate whether there was a correlation between the in vitro screening assay and what occurs in the intact animal where additional competing metabolic pathways and clearance mechanisms are present. The in vivo study was conducted with bile duct-cannulated male Sprague-Dawley rats. Three 2,5-diaminothiophene derivatives (compounds 1, 3, and 4) and one 2-diaminothiophene derivative (compound 7) were administered via an intravenous bolus at a dose of 5 mg/kg. Bile fluids were collected at designated time intervals and analyzed by HPLC/UV/MS. The in vivo results were consistent with the in vitro data in that all three 2,5-diaminothiophene derivatives formed GSH conjugates in vivo, followed by hepatic excretion into bile (Table 5) . Approximately 2 to 8% of the total dose of test compounds formed GSH conjugates in liver, and the conjugates were excreted into bile within 4 h (Fig. 8). A majority of the GSH conjugates were rapidly secreted into bile in the 1st h. No GSH conjugate was detected from the 2,5-diaminothiophene derivative (compound 7).
Discussion
P450s are the major metabolizing enzymes converting lipophilic xenobiotics and endogenous compounds to hydrophilic metabolites for direct elimination or as substrates for further conjugation catalyzed by phase II enzymes to generate polar and water-soluble compounds for renal or biliary excretion. In some cases, chemically reactive metabolites are generated during this process. Reactive metabolites are capable of covalently binding to proteins, DNA, or other cellular components, resulting in a variety of different types of toxicities, including cytotoxicity, acute organ toxicity, and idiosyncratic reactions. Therefore, it is essential to screen drug candidates for reactive metabolite formation and assess the potential risk in drug discovery and development. It is desirable to eliminate metabolic activation via structural modifications early in the drug discovery process, thus mitigating any potential risks in later clinical studies and before marketing approval. A key to this process is understanding the metabolic activation mechanism, which in turn can lead to the elimination of reactive metabolites through rational drug design.
Some thiophene-containing drugs and chemicals produce reactive metabolites and exhibit toxicity, such as TA, suprofen, methapyrilene, ticlopidine, and clopidogrel. The reactive metabolites generated from these drugs further inactivate their metabolizing enzyme, CYP2C9 (Ló pez- Garcia et al., 1994; Jean et al., 1996; O'Donnell et al., 2003; Hutzler et al., 2009 ). The metabolic activation mechanism is known to be determined by the structure and substitution pattern on the thiophene ring. For example, the thiophene moiety from TA and suprofen undergoes S-oxidation (Dansette et al., 1992 (Dansette et al., , 2005 O'Donnell et al., 2003; Medower et al., 2008) or thiophene ring epoxidation (O'Donnell, 2003; Dansette et al., 2005) , followed by nucleophilic attack on the thiophene ring and deoxygenation or dehydration to form protein adducts or GSH conjugates (Fig. 9) . Alternatively, the thiophene moiety from ticlopidine and clopidogrel is oxidized at the C2 position to form a thiolactone metabolite, followed by cleavage of the thioester bond to yield a reactive thiol that can bind to proteins (Dansette et al., 2009 ). The S-oxidation and epoxidation mechanisms have been widely accepted for the metabolic activation for thiophene derivatives. The S-oxidation mechanism was supported by evidence of the formation of thiophene S-oxide in vitro and in vivo or its 1,4-Michael addition product or sulfoxide dimers from the DielsAlder dimerization (Dansette et al., 2005; Medower et al., 2008) . The epoxidation mechanism is supported by indirect evidence with bioactivation of 2-(4-methoxybenzoyl)thiophene in the presence of 18 O 2 . The incorporation of 18 O into the 5-hydroxythiophene metabolite indicated an epoxide intermediate pathway (Dalvie et al., 2002; O'Donnell et al., 2003) . Furthermore, in the study of bioactivation of 2-phenylthiophene by rat liver microsomes in the pres- ence of GSH, a metabolite was isolated and identified as the product of GSH nucleophilic attack to the 4,5-epoxide of 2-phenylthiophene (Dansette et al., 2005) . This provided direct evidence for the epoxidation pathway in thiophene metabolic activation. In the same study, both the S-oxide dimer and 1,4-Michael addition product of GSH and S-oxide were identified. These data supported dual metabolic activation mechanisms for thiophene derivatives, S-oxidation and epoxidation, catalyzed by P450 enzymes. However, the metabolic activation of diamino-substituted thiophene derivatives has not been reported, and the mechanism is unknown. In this work, thiophene derivatives with mono or diamino substitution were dmd.aspetjournals.org tested in vitro and in vivo. Some of the thiophene derivatives, namely the 2,5-diamino series, were metabolically activated to form reactive intermediates that were subsequently trapped by electrophiles, such as GSH or NAC. No sulfoxide, sulfoxide dimer, or hydroxylation metabolites were detected with this series. Based on consideration of the structure of 2,5-diaminothiophenes, the thiophene ring can be considered a heteroaromatic system somewhat similar to 1,4-diaminobenzene. Upon the removal of a proton (oxidation) from one of the nitrogens adjacent to the sulfur atom (C2 or C5) an extended series of conjugated double bonds is formed, which is subject to nucleophilic attack at the C3 atom. This reactive intermediate is a 2,5-diimine metabolite and is analogous to several well known reactive 1,4-quinoid species (e.g., quinones, quinone methides, and quinone imines) formed from the oxidation of phenyl rings with the appropriate substituents attached (Monks and Jones, 2002; Kalgutkar and Didiuk, 2009) . Thus, we propose a novel metabolic activation mechanism, "2,5-diimine thiophene reactive intermediate," for 2,5-diaminothiophene derivatives, distinct from the previously described sulfur oxidation and epoxidation pathways (Fig. 10) . Based on the proposed mechanism, only compounds with amine groups adjacent to the sulfur atom (C2 and C5) are capable of generating the reactive intermediate. In support of this mechanism, none of the 2-amino or 2,4-diaminothiophene derivatives formed GSH conjugates under the same reaction conditions (Fig. 11) . In particular, the contrast in metabolic activation between 2,5-diamino and 2,4-diaminothiophene derivatives excluded the sulfur oxidation and epoxidation mechanisms. Our results further demonstrate that thiophene metabolic activation mechanisms are structuredependent. Thiophene derivatives are oxidized via multiple mechanisms and form reactive intermediates that might yield diverse adverse effects.
In this case, an understanding of the novel mechanism of 2,5-diaminothiophene bioactivation allowed the rational design of analogs that did not have this potential liability. In vitro reactive metabolite screening assays, i.e., using thiol-containing reagents such as GSH and NAC, are widely used in metabolite identification and structure modification efforts to eliminate potential covalent protein binding in early drug discovery. In addition, radiolabeled or unlabeled compound are administered to preclinical animals to assess the extent of covalent binding in vivo and potential toxicities. These can provide significant value in establishing an in vitro/in vivo correlation in regard to metabolic activation as well as observed toxicities. Even though reactive metabolites form in vitro, the extent of their formation in vivo and any associated toxicities may be quite different and depend on several factors, including the specific "alert" structure, metabolic activation mechanism, or pharmacokinetic profile. In vivo, natural defense systems may coordinate multiple clearance mechanisms in an efficient and synergistic way to detoxify via removing parent drugs and/or potential reactive metabolites. For instance, phase II enzymes, in conjunction with phase I enzymes, convert drugs/metabolites to water-soluble molecules to eliminate them from body. Endogenous nucleophiles, such as GSH, which is present in the liver at concentrations as high as 10 mM, effectively quench reactive intermediates generated by metabolizing enzymes. In addition, efflux transporters efficiently pump out xenobiotics and protect cells and tissues from potential toxicities. A trend was recently observed between the body burden of total daily reactive metabolite formation and the occurrence of drug-induced toxicity from a study comparing reactive metabolite formation with a series of 12 marketed drugs (Gan et al., 2009) . Drugs were associated with toxicity when FIG. 9 . Known bioactivation mechanism for thiophene derivatives via sulfur oxidation and epoxidation. The metabolic activation pathways are also proposed by (O'Donnell et al., 2003; Medower et al., 2008) . the total daily body burden of reactive metabolites exceeded 10 mg/day but not when the reactive metabolite burden was less than 1 mg/day.
In the present study, reactive metabolite formation in vivo correlated well with the in vitro assay when the 2,5-diamino-and 2-aminothiophene derivatives were screened. Furthermore, GSH conjugates of 2,5-diaminothiophene derivatives were detected in the bile at the level of Ͻ10% of total dose (compounds 1, 3, and 4), together with 30 to 50% of parent compounds (data not shown), from bile duct-cannulated rat studies. In a separate study, multidrug resistance-associated protein 2 and breast cancer resistance protein were identified as efflux transporters that excreted parent compounds into bile (Sampson et al., 2008) . This biliary excretion of parent compound by multidrug resistance-associated protein 2 leveraged the body burden on metabolic activation and GSH depletion and also reduced covalent binding-mediated risk. However, further studies are needed to address whether the 2,5-diaminothiophene derivatives could generate significant adverse effects. The species difference and translational toxicology from preclinical animals to human would also need to be considered. Increased knowledge in this area is highly desired.
In summary, the metabolic activation of a series of mono-and diamino-substituted thiophene derivatives was fully investigated both in vivo and in vitro. Multiple human P-450 enzymes catalyzed the formation of reactive metabolites with CYP3A4 being the most predominant. A novel metabolic activation mechanism for thiophene derivatives was proposed, generating a reactive 2,5-diimine thiophene intermediate. This underscores the complexity of metabolic activation mechanisms for thiophene derivatives, which primarily depend on the substitution pattern on the thiophene ring. Our results expand the knowledge around structural alerts with the thiophene moiety. The proposed mechanism was used to guide structural modifications to eliminate metabolic activation via the disruption of the formation of the 2,5-diimine thiophene reactive intermediate. Our results also provide an example of a rational approach in drug design to mitigate potential safety risks in drug discovery and development.
